{
  "ticker": "EYE",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02975012",
  "id": "02975012",
  "pages": 16,
  "price_sensitive": false,
  "date": "20250731",
  "time": "0924",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250731/pdf/06mc6jv7qtndt1.pdf",
  "summary": "### **Summary of Nova Eye Medical Limited (ASX:EYE) Announcement \u2013 Quarterly Report (30 June 2025)**  \n\n#### **Key Financial & Operational Highlights:**  \n- **FY25 Revenue**: Record **A$29.2M** (up **23%** in constant currency), meeting guidance.  \n- **Glaucoma Segment**: Achieved **positive EBITDA in H2 FY25**, aligning with prior outlook.  \n- **Cash Flow**: Q4 operational outflow reduced to **A$847K**; **cash balance A$5.1M** at 30 June 2025.  \n- **FY26 Guidance**:  \n  - Revenue (ex-China): **US$21M\u2013US$24M** (A$32M\u2013A$37M).  \n  - Targeting **breakeven EBITDA in H1 FY26**.  \n\n#### **Market & Strategic Updates:**  \n- **iTrack Advance**: Gaining traction in U.S. (Needham & Co projects market share rising to **3.4% by mid-2026**).  \n- **China Approval**: iTrack Advance regulatory approval expected late 2025; legacy iTrack sales continue.  \n- **Drug Delivery**: Pharma partnership evaluation pending (results expected H1 FY26).  \n- **Grant Award**: **A$488K** for eye-disease detection tech development (govt. Critical Technologies Program).  \n\n#### **Clinical & Reimbursement:**  \n- Strong reimbursement stability in U.S. (**CMS 2026 rates: US$2,231 facility fee + US$542 surgeon fee**).  \n- iTrack real-world data from **500+ eyes** in International Glaucoma Surgery Registry (IGSR).  \n\n**No material capital-raising or trading halt details identified.**",
  "usage": {
    "prompt_tokens": 3541,
    "completion_tokens": 366,
    "total_tokens": 3907,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-30T23:42:52.723421"
}